Close

Join Experts and Patients in NYC for a Day of Learning and Connecting Register Free Today

Immunotherapy By Cancer Type

Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link
Impacting All Cancers

From the preventive vaccine for cervical cancer to the first therapy ever proven to extend the lives of patients with metastatic melanoma, immunology has already led to major treatment breakthroughs for a number of cancers. Every cancer type is unique, though, and immunology and immunotherapy are impacting each cancer in different ways.

Bladder Cancer
Bladder cancer is the 6th most common cancer in the US. Approved by the FDA in 1990, bladder cancer immunotherapy treatments continue to develop in clinical trials today.
Brain Cancer
Malignant brain tumors are a relatively rare but very serious form of cancer. Immunotherapy is showing significant promise where other approaches have failed.
Breast Cancer
Breast cancer is one of the most commonly diagnosed cancers in women worldwide. Immunotherapy research in breast cancer is ongoing and holds the promise of new treatment and clinical trial options.
Cervical Cancer
Cervical cancer, typically caused by the human papillomavirus (HPV), is one of the major cancer types for which new immunotherapy treatments are being developed.
Childhood Cancer
Cancer affects an estimated 300,000 young people every year. Immunotherapy has the potential to improve both their survival and quality of life.
Colorectal Cancer
Colorectal cancer is one of the most common types of cancer. Immunotherapy is an exciting area of treatment for colorectal cancer.
Esophageal Cancer
While surgery is the most common treatment for esophageal cancer, the 5-year survival rate is 40% for localized disease. Better, immune-based therapies are badly needed.
Head and Neck Cancer
Head and neck cancer is a relatively uncommon but very serious cancer. Immunotherapies are showing significant promise where other approaches have failed.
Kidney Cancer
Kidney cancer is one of the 10 most common cancers. Immunology research is ongoing in kidney cancer, with many possible treatments being studied.
Leukemia
Leukemia is one of the most common types of blood cancer. Immunotherapies are showing significant promise where other approaches have failed.
Liver Cancer
When diagnosed early, liver cancer can be treated with surgery, but few options exist for advanced disease patients. Clinical trials are developing immune-based treatments for advanced liver cancers.
Lung Cancer
Lung cancer is one of the most common types of cancer worldwide. Immunotherapy is greatly improving treatment and prognosis for patients with lung cancer.
Lymphoma
Lymphoma is a relatively uncommon but very serious cancer. Immunotherapies are showing significant promise where other approaches have failed.
Melanoma
Melanoma has traditionally been treated surgically. However, it is also one of the cancers most responsive to immunotherapy.
Multiple Myeloma
Multiple myeloma originates in plasma cells, a type of white blood cell that makes antibodies. Immunotherapy clinical trials have shown promise for better myeloma treatments.
Ovarian Cancer
Ovarian cancer may respond to chemotherapy, however, up to 80% of women relapse. Immunotherapy represents one new avenue for these women.
Pancreatic Cancer
Pancreatic cancer is a relatively uncommon but very serious cancer. Immunotherapies are showing significant promise where other approaches have failed.
Prostate Cancer
Prostate cancer is the one of the most commonly occurring cancers in American men. Immunotherapy is an exciting area of treatment for prostate cancer.
Sarcoma
Unfortunately, many sarcoma patients treated with surgery and chemo will develop metastatic disease. Immunotherapy clinical trials provide hope for the development of new sarcoma treatments.
Stomach Cancer
The 5th most common and 3rd most deadly cancer worldwide, stomach cancer, or gastric cancer, is a core focus of immune-based treatment clinical trials today.

*Immunotherapy results may vary from patient to patient.

Contact Us

National Headquarters | One Exchange Plaza
55 Broadway, Suite 1802 | New York, NY 10006

(800) 992-2623(212) 832-9376Staff Directory

Stay Connected with CRI

Follow us
Top